August 8, 2018 09:35 AM EDTUpdated 10:48 AM
News Briefing

Prof­its sink­ing, My­lan looks to strate­gic al­ter­na­tives; No­vo posts de­press­ing Q2

Brittany Meiling

→ It seems My­lan $MYL can’t catch a break. Fol­low­ing a CRL ear­li­er this sum­mer, the com­pa­ny re­port­ed out earn­ings Wednes­day morn­ing for Q2 that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times